심장재동기화치료 기기 시장 : 시장 규모, 점유율, 동향 분석(2025-2032년)

Global Cardiac Resynchronization Therapy Device Market Report

The global cardiac resynchronization therapy device market was valued at $2.98 billion in 2025. Over the forecast period, the market is expected to grow at a CAGR of 0.7% to reach approximately $3.1 billion by 2032.

The full report suite on the global market for cardiac resynchronization therapy, or CRT, devices includes cardiac resynchronization therapy-pacemakers and cardiac resynchronization therapy-defibrillators. This report follows the same structure and content order shown in the attached example document, adapted to the global CRT market and its specific clinical, competitive and reimbursement dynamics .

This report provides detailed analysis of unit sales, average selling prices, procedure numbers, market size and growth trends, with historical data to 2022 and market forecasts through 2032. It also includes market drivers and limiters, recent mergers and acquisitions, company profiles, product portfolios and leading competitors. The result is a focused strategic view of a highly specialized but clinically important segment within cardiac rhythm management.

Growth in the category is steady rather than rapid. The number of devices is expected to rise gradually as the global population ages and more patients become candidates for heart failure device therapy. Within the market, CRT-D systems continue to hold particular importance because many physicians prefer to include defibrillation capacity when the patient can afford it and when clinical risk supports the added protection. Growth potential is also somewhat stronger in lower-income countries over the long term as healthcare access improves, though this remains closely tied to reimbursement policy and local device affordability.

Overall, the global CRT market is a stable, clinically durable category supported by heart failure burden, aging populations and the continued value of device-based therapy in reducing long-term healthcare utilization. While it does not show the same growth rate as faster-moving EP or leadless pacing segments, it remains an important pillar of the global cardiac device industry.

Market Overview

The global cardiac resynchronization therapy device market includes implantable systems designed to treat heart failure patients with ventricular dyssynchrony. These devices coordinate contraction between the ventricles to improve cardiac efficiency, reduce symptoms and support better long-term clinical outcomes in appropriately selected patients. The market includes both CRT-P systems, which provide pacing only, and CRT-D systems, which combine resynchronization therapy with defibrillation capability.

CRT occupies a distinct role within the broader cardiac rhythm management landscape. Unlike standard pacemakers, CRT systems are used in more clinically complex patients who often have significant heart failure burden and structural disease. This means the therapy is less about simple rhythm support and more about improving cardiac performance, reducing hospitalization and managing long-term morbidity. Because of this, CRT remains one of the more clinically impactful segments in implantable cardiac devices, even though its growth rate is modest.

A major internal dynamic within the market is the relationship between CRT-P and CRT-D. In many settings, physicians prefer CRT-D because it adds protection against life-threatening ventricular arrhythmias in patients already at high risk. When financially feasible and clinically justified, this pushes utilization toward the higher-value segment of the market. At the same time, reimbursement policy, national treatment pathways and hospital budget pressure can influence how frequently CRT-D is selected over CRT-P.

The market is also influenced by the maturity of the technology. CRT is now a well-established therapy category with broad physician familiarity and a relatively concentrated competitive landscape. That maturity supports steady demand but also limits upside from first-time adoption in developed regions. As a result, growth depends more on demographic expansion, clinical replacement need, device refresh cycles and selective growth in emerging healthcare systems than on dramatic broadening of the treatment base.

Market Drivers

Use of CRT Devices to Reduce Surgical and Long-Term Care Cost

One of the main drivers of the global CRT market is the therapy's ability to reduce long-term treatment burden in heart failure patients. Cardiovascular disease remains the leading cause of death worldwide, responsible for more than 20 million deaths annually. In Europe alone, cardiovascular disease accounts for about 3.9 million deaths each year, representing roughly 40% of all deaths. This places enormous pressure on health systems through repeat hospital admissions, worsening heart failure and high long-term care costs.

CRT devices continue to gain support because they help improve patient stability and reduce readmission rates. In patients who respond well, the therapy can lessen downstream healthcare utilization and improve quality of life. This makes CRT valuable not only from a patient care perspective but also from a health economics perspective. Hospitals and payers continue to recognize this value, which supports the category even when upfront implant costs remain high.

Lifesaving Potential of CRT-D Systems

The lifesaving potential of CRT-D remains another major market driver. Large clinical trials, especially the MADIT CRT series, have shown that CRT-D systems can successfully terminate life-threatening ventricular arrhythmias in more than 98% of events. That level of protection stands in sharp contrast to the poor survival typically seen after out-of-hospital sudden cardiac arrest, where real-world survival often remains below 10%.

This strong survival advantage continues to support physician preference for CRT-D in eligible patients. Even though CRT-D systems cost more than CRT-P devices, the additional protection they provide makes them highly attractive where patient affordability and reimbursement allow. This is one of the main reasons CRT-D continues to hold such an important position within the overall CRT market.

Aging Population and Expanding Heart Failure Burden

The market also benefits from demographic change. As populations age, the number of patients with heart failure, conduction abnormalities and structural heart disease continues to rise. This expands the pool of patients who may be evaluated for CRT. Although the category is mature, demographic pressure continues to support procedure demand in most global markets.

This trend is especially important because CRT candidacy often overlaps with older age and accumulated cardiovascular burden. Even modest annual increases in eligible patients can sustain the market over time, particularly when combined with stable replacement demand and ongoing heart failure incidence.

Market Limiters

Recall of Device and or Leads

One of the largest limiters in the CRT market is the effect of device or lead recalls. In implantable cardiac therapy, recalls can have a strong and immediate effect on physician trust, hospital purchasing behavior and company profitability. Once a competitor suffers a reliability event, other suppliers often move aggressively to capture displaced accounts.

This dynamic matters especially in CRT because the procedures are high value and the patients are medically complex. Reliability concerns can therefore influence procurement decisions for multiple quarters or longer. Even if the total market need remains stable, recalls can create short-term disruption and increase regulatory attention across the category.

High Cost of CRT Implantation Procedures

A second major limiter is the high overall cost of CRT implantation. CRT procedures remain among the more expensive cardiac device interventions, and total implant cost has not meaningfully decreased in recent years. This affects both CRT-P and CRT-D, although the financial burden is naturally greater in the defibrillator segment.

Because the procedures remain expensive for hospitals and patients, affordability continues to limit how many can be performed. This is particularly important in regions where reimbursement is incomplete or where hospitals face tighter budget controls. As a result, unit growth stays constrained even though the therapy has clear clinical value.

Market Maturity

Another limiter is the maturity of the category itself. CRT is already well established in many developed healthcare systems, and the therapy guidelines are mature. This means growth is not being driven by a dramatic new expansion in the number of eligible patients receiving first-time therapy. Instead, it is driven more by demographics, replacement procedures and selective expansion in less penetrated regions. That dynamic supports stability, but it also limits overall growth rate.

Market Coverage and Data Scope

Quantitative Coverage

Market size, market shares, market forecasts, market growth rates, units sold and average selling prices.

Qualitative Coverage

Market drivers and limiters, growth trends, recent mergers and acquisitions, company profiles, product portfolios and leading competitors.

Time Frame

Base year 2025, historical data to 2022 and forecasts through 2032.

Data Types Included

Unit sales, average selling prices, procedure numbers, market size and growth trends.

This report is designed to support strategic planning, competitive benchmarking and product positioning by combining detailed CRT market sizing with practical analysis of clinical demand, pricing pressure and reimbursement-driven adoption.

Markets Covered and Segmentation

• The report covers the Global Cardiac Resynchronization Therapy Device Market, further segmented into:

CRT-P Market

This segment includes cardiac resynchronization therapy-pacemakers used in heart failure patients requiring ventricular resynchronization without defibrillation support.

CRT-D Market

This segment includes cardiac resynchronization therapy-defibrillators that combine resynchronization therapy with implantable defibrillation capability.

Each segment is analyzed by unit sales, average selling prices and total market value, with forecasts through 2032 and historical data to 2022. This segmentation reflects the core decision framework within the CRT market, where therapy selection often depends on both heart failure needs and arrhythmic risk profile.

Competitive Analysis

Medtronic remains the global leader in the CRT market across both CRT-D and CRT-P segments. Its current portfolio includes Cobalt, Crome, Percepta, Serena and Solara. These systems incorporate adaptive CRT algorithms, heart failure diagnostics and long-term device longevity that continue to support the company's leadership across major implanting centers. Medtronic's combination of broad portfolio depth, physician familiarity and installed base presence gives it a durable leading position through 2025.

Boston Scientific is the second-largest competitor and has modernized its CRT portfolio well beyond older legacy systems. In CRT-D, the company competes with platforms such as RESONATE and VIGILANT, which emphasize extended battery longevity and advanced heart failure diagnostics. In CRT-P, Boston Scientific continues to support its position through the VALITUDE and INGENIO families, which provide broad MRI conditional labeling and dependable pacing performance. This refreshed lineup helps the company maintain a stable share position across large heart failure programs.

Abbott holds the third-largest global CRT share, supported by systems such as Entrant, Gallant and Quadra Allure MP, alongside other updated CRT-D and CRT-P platforms. Abbott emphasizes multipoint pacing, advanced heart failure management functions and strong remote monitoring capabilities. Consistent reliability and refreshed performance characteristics have helped the company remain a strong competitor in the global market through 2025.

Overall, the competitive landscape is shaped by long-standing physician relationships, generator longevity, heart failure diagnostics, remote monitoring strength and the ability to support both pacing-only and defibrillation-inclusive CRT therapy.

Technology and Practice Trends

One of the most important trends in the CRT market is the continued preference for CRT-D where patient condition and affordability support it. Physicians often favor the addition of defibrillation because of the extra protection it provides in high-risk heart failure populations.

Another important trend is the increasing value of heart failure diagnostics and remote monitoring. Modern CRT systems do more than pace. They help clinicians manage chronic heart failure through data collection, event alerts and more efficient follow-up workflows.

Battery longevity remains a key product trend as well. Longer service life supports better long-term economics and reduces replacement burden in a patient group that is already clinically complex.

Finally, MRI conditional labeling and platform refinement continue to standardize expectations across the category. These improvements do not radically change the therapy itself, but they strengthen device value and help preserve clinical confidence in a mature market.

Geography

This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.

108 pages of detailed market analysis, segmentation and forecast data.

Methodology Appendix and Acronym Glossary.

Why This Report

Where are the most stable opportunities in the global CRT market through 2032?

How is the balance between CRT-P and CRT-D expected to evolve across global markets?

What role do heart failure burden, aging populations and reimbursement policy play in shaping unit demand?

How do device recalls and high procedure costs affect competition and adoption?

Which companies hold the strongest positions in CRT-P and CRT-D, and how durable are those advantages?

How can suppliers, investors and strategy teams assess opportunity in a mature but clinically critical heart failure device category?

The Global Cardiac Resynchronization Therapy Device Market Report from iData Research answers these questions with detailed market sizing, pricing analysis, segmentation and competitive intelligence. Use it to benchmark competitors, understand therapy demand and support strategy in a stable but strategically important segment of cardiac rhythm management.

TABLE OF CONTENT

List Of Figures

List Of Charts

Research Methodology

• Step 1: Project Initiation & Team Selection
• Step 2: Prepare Data Systems And Perform Secondary Research
• Step 3: Preparation For Interviews & Questionnaire Design
• Step 4: Performing Primary Research
• Step 5: Research Analysis: Establishing Baseline Estimates
• Step 6: Market Forecast And Analysis
• Step 7: Identify Strategic Opportunities
• Step 8: Final Review And Market Release
• Step 9: Customer Feedback And Market Monitoring

Impact Of Global Tariffs

Cardiac Resynchronization Therapy Device Market

• 6.1.1 Global Cardiac Resynchronization Therapy Device Market Overview
• 6.1.2 Competitive Analysis
• 6.1.3 Procedures Included
• 6.1.4 Markets Included
• 6.1.5 Regions Included

Introduction

• 6.1.6 Cardiac Resynchronization Therapy-Pacemakers (Crt-Ps)
• 6.1.7 Cardiac Resynchronization Therapy-Defibrillators (Crt-Ds)

Procedure Numbers

• 6.1.8 Total Crt Placement Procedures
• 6.1.9 Initial Placement Crt Procedures
• 6.1.10 Replacement Crt Procedures

Market Overview

• 6.1.11 By Segment
• 6.1.12 By Region

Market Analysis And Forecast

• 6.1.13 Total Crt Device Market
• 6.1.14 Crt-P Market
  • 6.1.14.1 Initial Placement Crt-P Market
  • 6.1.14.2 Replacement Crt-P Market
• 6.1.15 Crt-D Market
  • 6.1.15.1 Initial Placement Crt-D Market
  • 6.1.15.2 Replacement Crt-D Market

Drivers And Limiters

• 6.1.16 Market Drivers
• 6.1.17 Market Limiters

Competitive Market Share Analysis

Abbreviations